/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.
/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.
- XPOVIO® (selinexor) approvals received in Mainland China, Australia, South Korea and Singapore, expect Hong Kong and Taiwan in remainder of 2022. - 2021 Revenue of RMB28.8 million, Named Patient Program paving way for strong commercial launch in 2022. - Broad and deep clinical program of 18 studies, including 5 registrational studies, ongoing across multiple regions. - Strong cash,.
Antengene Provides an Update on Its Latest Developments prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.